US Government Simulation
S. 29Debating

Affordable Insulin and Prescription Drug Competition Act

Started 5 total speeches
§

Bill Text: S. 29

Official Text (Amendment #1 — Adopted (Current))

119TH CONGRESS

S. 29

IN THE SENATE OF THE UNITED STATES
January 1, 2025
Sen. Collins of Maine introduced the following bill

A BILL

To cap monthly out-of-pocket insulin costs for patients with commercial health insurance, prohibit anti-competitive Pharmacy Benefit Manager practices, expedite Food and Drug Administration review of generic biosimilar insulin products, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "Affordable Insulin and Prescription Drug Competition Act".

SECTION 2. LIMITATION ON COMMERCIAL INSULIN COST-SHARING.

a) No pharmaceutical manufacturer, wholesaler, or pharmacy shall charge a total wholesale or retail list price exceeding $20 per vial or $35 per thirty-day supply of prescription insulin for any patient in the United States, whether insured or uninsured.

b) Cost-sharing limitations under this section shall apply regardless of whether the enrollee has satisfied the plan's annual deductible.

c) PROTECTION FOR UNINSURED AND CASH-PAYING PATIENTS.—Any individual without health insurance coverage, or whose coverage is not applied at the point of sale, shall be entitled to purchase covered insulin products at any licensed pharmacy for no more than the $20 per vial or $35 per thirty-day supply ceiling established under subsection (a).

d) PROHIBITION ON PREMIUM SHIFTING AND CROSS-DRUG PRICE HIKES.—

  1) Health insurance issuers shall not increase annual plan premiums or deductibles to offset reduced insulin cost-sharing.

  2) Pharmaceutical manufacturers subject to this section shall be prohibited from increasing the wholesale acquisition cost of other life-saving prescription medications above the rate of medical inflation to compensate for reduced insulin revenues.

SECTION 3. PHARMACY BENEFIT MANAGER TRANSPARENCY AND FAIRNESS.

a) Pharmacy Benefit Managers (PBMs) shall not charge a health plan or patient a co-payment or reimbursement rate for prescription insulin that exceeds the net acquisition cost of the medication.

b) No Pharmacy Benefit Manager shall restrict, penalize, or steer patients away from independent community pharmacies toward affiliated mail-order or retail pharmacies.

SECTION 4. EXPEDITED FDA APPROVAL OF BIOSIMILAR INSULIN.

a) The Food and Drug Administration (FDA) shall establish a priority review pathway for generic and interchangeable biosimilar insulin applications, issuing final determinations within 180 days of submission.

b) Brand-name pharmaceutical manufacturers shall be prohibited from entering into pay-for-delay settlements that postpone the market entry of approved biosimilar competitors.

SECTION 5. EFFECTIVE DATE.

This Act shall take effect on January 1 of the first calendar year following the date of enactment.

Debate

Chuck Schumer

Senate Minority Leader · Chuck Schumer

Mr. President, I strongly support S. 29 because no American should have to choose between insulin and other necessities. This bill caps insulin prices for insured and uninsured patients alike, regardless of deductibles, and prevents insurers from shifting those savings into higher premiums.

It also confronts the barriers that keep prices high: PBM steering away from independent pharmacies and pay-for-delay deals that block biosimilar competition. For families across New York, faster review and fair access can mean more affordable insulin at the pharmacy counter. I urge the Senate to pass this bill and yield the floor.

Lindsay Graham

Conservative Study Committee Senate Chair · Lindsay Graham

Mr. President, I support S. 29 because South Carolinians should not face an impossible choice when they need insulin. The bill sets a clear price ceiling for insured and uninsured patients, while curbing pharmacy benefit manager practices that can steer patients away from independent community pharmacies.

Most importantly, this bill pairs immediate affordability with competition: it directs the FDA to review biosimilar insulin applications within 180 days and bars pay-for-delay deals. More competitors can help bring prices down without asking families to wait for relief. I urge the Senate to pass S. 29 and yield the floor.

Henry Goodwill

U.S. Senator, DE (Class 1) · Henry Goodwill

Mr. President, I rise today in strong support of the Affordable Insulin and Prescription Drug Competition Act, S.29, because access to life-saving medication should never be a financial privilege, but a fundamental necessity. No American should have to choose between purchasing essential medicine and meeting their basic needs simply because treatment is beyond their financial means. This bill takes meaningful steps toward addressing this injustice by capping insulin costs, protecting uninsured and cash-paying patients, preventing unfair Pharmacy Benefit Manager practices, and expediting the approval of generic and biosimilar insulin. It recognizes that the affordability of medicine is not merely a matter of individual responsibility, but also of ensuring fairness and accountability within our healthcare system.

Furthermore, this legislation promotes competition and transparency within the pharmaceutical industry while protecting patients from excessive costs and anti-competitive practices. By removing barriers to affordable alternatives and preventing companies from circumventing these protections, we can move toward a healthcare system that prioritizes patients over excessive profits. Access to insulin is a matter of human dignity, compassion, and ultimately, the preservation of life. The government has a responsibility to ensure that no patient is denied essential treatment because of their financial circumstances. I urge the Senate to support and pass S.29 and yield the floor.

Chuck Schumer

Senate Minority Leader · Chuck Schumer

Mr. President, I rise in strong support of S. 29. No New Yorker should ration insulin because the price at the pharmacy counter is out of reach.

This bill makes affordability real for insured and uninsured patients alike, capping insulin at $20 per vial or $35 per month. But a cap alone is not enough: PBM steering can shut patients out of independent community pharmacies, while pay-for-delay deals can block lower-cost biosimilar competition. S. 29 tackles both barriers and directs the FDA to decide biosimilar applications within 180 days. Let us put patients ahead of these practices and pass this bill. I yield the floor.

Lindsay Graham

Conservative Study Committee Senate Chair · Lindsay Graham

Mr. President, I support S. 29 because South Carolinians who depend on insulin should not be priced out of a life-saving medicine. This bill sets a $20-per-vial or $35-per-month ceiling for insured and uninsured patients, and it addresses a root cause of high costs by accelerating biosimilar review and barring pay-for-delay agreements.

The Senator from New York rightly emphasized that competition matters; this legislation turns that principle into action by requiring FDA decisions within 180 days and preventing PBM steering away from independent pharmacies. Those steps offer relief while widening patient choice. I urge the Senate to pass S. 29 and yield the floor.